This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Ira Pastan, M.D.
Co-Chief at National Cancer Institute


Ira Pastan is co-chief of the Laboratory of Molecular Biology at the National Cancer Institute. Pastan and colleagues have developed Recombinant Immunotoxins (RITs) for the treatment of cancer. RITs are composed of a single chain Fv or an Fab attached to the active portion of Pseudomonas exotoxin A. One of these, Moxetumomab pasudotox, is FDA approved for the treatment of drug resistant Hairy Cell Leukemia. Another (LMB-100 ) targets mesothelin, a protein discovered in the Pastan lab and found to be highly expressed in mesothelioma and about 30% of human cancers. LMB-100 causes immunogenic cell death and in mouse modes cooperates with anti-CTLA4 to induce anti-tumor immunity. LMB-100 given with check point inhibitors is in clinical trials for mesothelioma and pancreatic cancer.

Agenda Sessions

  • Antibody Binding Sites as Therapeutics: scFv, VHH, VNAR and Beyond: A Tribute Session to Jim Huston's Invaluable Contributions Over his 45+ Year Career

  • Recombinant Immunotoxins Produce anti-tumor Immunity

    On Demand